Fedratinib TG101348

Name Value
Weight 524.691 g/mol
Zinc ID ZINC19862646
Smiles Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Molecular formula C27H36N6O3S
Mode of inhibition N/A
CAS 936091-26-8

Clinical Trials

Study title Status Conditions Link
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Recruiting Primary Myelofibrosis NCT04446650
A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects Completed Healthy Volunteers NCT04702464
A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment Recruiting Healthy Volunteers|Hepatic Impairment NCT03983161
Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects Completed Healthy Volunteers NCT03983239
A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants Not yet recruiting Healthy Volunteers NCT05051553
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Recruiting IDH Mutation|IDH1 Mutation|IDH2 Gene Mutation|Blood Cancer|Myeloproliferative Neoplasm NCT04955938
A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia Recruiting Primary Myelofibrosis|Post-Polycythemia Vera|Myelofibrosis NCT03755518
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms Recruiting Myeloproliferative Neoplasm NCT05127174
Individual Patient Compassionate Use of Fedratinib Available Myelofibrosis NCT03723148
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Recruiting Primary Myelofibrosis|Post-Polycythemia Vera|Myelofibrosis NCT03952039
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) Recruiting Myelofibrosis NCT04817007
Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin Completed Healthy Volunteers NCT04231435
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Recruiting Acute Myeloid Leukemia|Essential Thrombocythemia|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm|Myeloproliferative Neoplasm|Myeloproliferative Neoplasm, Unclassifiable|Polycythemia Vera|Primary Myelofibrosis|Secondary Myelofibrosis NCT04282187
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis Completed Myelofibrosis NCT00631462
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) Recruiting Myelofibrosis|Polycythemia Vera|Thrombocythemia NCT04629508
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis Completed Myelofibrosis NCT00724334
The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD) Completed Chronic Beryllium Disease (CBD)|Beryllium Sensitization (BeS) NCT02596347
Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors Not yet recruiting Myeloproliferative Neoplasm (MPN)|Myelofibrosis，MF NCT05153343
Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors Not yet recruiting Myeloproliferative Neoplasm (MPN)|Myelofibrosis，MF NCT05115344
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors Completed Neoplasm Malignant NCT01836705
A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis Recruiting Myelofibrosis NCT04562870
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis Recruiting Primary Myelofibrosis|Secondary Myelofibrosis NCT04370301

References

Publication DOI Pubmed PMCID

Vendors

Company Lnk to product
MedChemExpress https://www.medchemexpress.com/TG-101348.html
Selleckchem https://www.selleckchem.com/products/Fedratinib-SAR302503-TG101348.html

Filter data

Compound Fedratinib TG101348
Experiment types
Concentrations
Cell lines
Organisms
Animal models
STAT proteins
Other

Experiments

Compound Experiment type Investigated event Concentration Cell line Organism Animal model Stat protein Details